ライフサイエンスコーパス: impetigo

1 261 (18.7%) had scabies and 347 (24.8%) had impetigo.

2 evalence of scabies and, to a lesser extent, impetigo.

3 s efficacious for the control of scabies and impetigo.

4 Handwashing with daily bathing also prevents impetigo.

5 eratinocytes in a manner that emulates human impetigo.

6 ve in reducing the prevalence of scabies and impetigo.

7 dies to reduce the prevalence of scabies and impetigo.

8 e efficacy of MDA for scabies on scabies and impetigo.

9 reports on the impact of MDA on scabies and impetigo.

10 able for meta-analysis for scabies and 4 for impetigo.

11 inistration on the prevalence of scabies and impetigo 3 years after the intervention.

12 (-65% to -41%) and a 34% lower incidence of impetigo (-52% to -16%).

13 r, urticaria, scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, ce

14 The prevalence of impetigo also declined in all groups, with the greatest

15 inistering azithromycin on the prevalence of impetigo and antimicrobial resistance.

16 nt of suppurative complications (eg, quinsy, impetigo and cellulitis, otitis media, and sinusitis) or

17 ublic health problem in many countries, with impetigo and its complications important consequences.

18 In the blistering diseases bullous impetigo and staphylococcal scalded-skin syndrome, patho

19 strategies to suppress blistering in bulbous impetigo and staphylococcal scalded-skin syndrome.

20 Primary study outcomes were diarrhoea, impetigo, and acute respiratory-tract infections (ie, th

21 ococcal diseases: uncomplicated pharyngitis, impetigo, and acute rheumatic fever.

22 he incidence of acute respiratory infection, impetigo, and diarrhoea.

23 lating the superficial human skin infection, impetigo, and providing a model system for testing this

24 erficial infections, such as pharyngitis and impetigo, and severe invasive infections.

25 However, pharyngitis and impetigo are rarely observed prior to invasive disease,

26 s, we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline.

27 Bullous impetigo due to Staphylococcus aureus is one of the most

28 e change in the prevalence of scabies and of impetigo from baseline to 12 months.

29 ns involve the throat (pharyngitis) or skin (impetigo); however, the factors that determine tissue tr

30 the prevalence of both scabies and secondary impetigo; however, their effect at large scale is untest

31 onducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solo

32 m Group A Streptococcus (GAS) pharyngitis or impetigo in children and adolescents, which may evolve t

33 igated the human serological response to GAS impetigo in Fijian schoolchildren, focusing on 3 major e

34 We report here the prevalence of scabies and impetigo in residents of the ten baseline villages compa

35 sing strategy for the control of scabies and impetigo in settings where the diseases are endemic.

36 Indeed, in human impetigo infection, we found high epidermal expression o

37 Where impetigo is the dominant mode of transmission, circulati

38 fter an upper respiratory tract infection or impetigo; its occurrence in older patients is not well c

39 ococci are the nasopharyngeal mucosa and the impetigo lesion.

40 ins bearing emm gene markers associated with impetigo lesions as the principal tissue reservoir, but

41 The proportion of impetigo lesions containing pyogenic streptococci declin

42 The proportion of impetigo lesions containing Staphylococcus aureus detect

43 We collected impetigo lesions swabs at baseline, 3 and 12 months to d

44 pattern D strains are usually recovered from impetigo lesions; as a group, emm pattern E organisms fa

45 ility data were available for the infection (impetigo or cellulitis with purulent drainage but no abs

46 ominate in organisms with the emm marker for impetigo (pattern D).

47 and is expressed by some strains that cause impetigo, pharyngitis and acute glomerulonephritis.

48 We measured scabies and impetigo prevalence at baseline and 12 months.

49 ctin led to similar decreases in scabies and impetigo prevalence compared to ivermectin alone.

50 tcome assessed was the change in scabies and impetigo prevalence following MDA.

51 MDA for scabies also led to a reduction in impetigo prevalence with a relative reduction of 66%.

52 At baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermec

53 ion 88%, 95% CI 76.5-99.3) and 81 (6.4%) had impetigo (relative reduction 74%, 63.4-84.7).

54 al five skin problems were pruritus, eczema, impetigo, scabies, and molluscum contagiosum.

55 diseases including pharyngitis, tonsillitis, impetigo, scarlet fever, streptococcal toxic shock syndr

56 ropical disease of the skin that can lead to impetigo, serious secondary bacterial infections and imm

57 In bullous impetigo, Staphylococcus aureus spreads under the stratu

58 In an DeltafbaA mutant constructed in the impetigo strain Alab49, loss of FbaA resulted in a sligh

59 ocytes, we hypothesized that adherence of an impetigo strain of S. pyogenes would be promoted by term

60 Adherence of only the impetigo strain, and not the pharyngeal strain of S. pyo

61 deration of the histopathology of nonbullous impetigo that shows localization of Streptococcus pyogen

62 in GAS fitness in a humanized mouse model of impetigo; the DeltafbaA mutant also exhibited decreased

63 are distinct from strains that tend to cause impetigo; thus, genetic differences between them may con

64 as a range of diseases from pharyngitis and impetigo to severe outcomes such as necrotizing fasciiti

65 ety of human diseases including pharyngitis, impetigo, toxic shock, and necrotizing fasciitis, as wel

66 incidence for streptococcal pharyngitis and impetigo varies with season and locale, leading to wide

67 The prevalence of impetigo was 9.6% (95% CI, 8.1%-11.4%), significantly lo

68 I, 6.6-603.2), and the highest prevalence of impetigo was among children aged 5-9 years (16.4%; adjus

69 It is associated with impetigo, which can lead to serious systemic complicatio

70 administration of ivermectin for scabies and impetigo, with coadministration of azithromycin for trac

71 rategies include programs targeting scabies, impetigo, yaws, and diseases causing lymphoedema.